Belatacept: Is there BENEFIT for liver transplantation too?

S. J. Knechtle; A. B. Adams

doi:10.1111/ajt.12806

Belatacept: Is there BENEFIT for liver transplantation too?

S. J. Knechtle, A. B. Adams

Research output: Contribution to journal › Editorial › peer-review

11 Scopus citations

Abstract

The results of the multicenter belatacept liver transplant trial disappoint with respect to safety and efficacy, and new approaches will be required before this agent plays a role in liver transplant immunosuppression. See article by Klintmalm et al on page 1817.

Original language	English (US)
Pages (from-to)	1717-1718
Number of pages	2
Journal	American Journal of Transplantation
Volume	14
Issue number	8
DOIs	https://doi.org/10.1111/ajt.12806
State	Published - Aug 2014
Externally published	Yes

Bibliographical note

Funding Information:
The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. SJK is a stockholder of Bristol Myers Squibb. ABA receives grant money from Bristol Myers Squibb.

Access

10.1111/ajt.12806

OpenUrl availability

Full text

Cite this

@article{f032144189634b8dbb97b764997e81d4,

title = "Belatacept: Is there BENEFIT for liver transplantation too?",

abstract = "The results of the multicenter belatacept liver transplant trial disappoint with respect to safety and efficacy, and new approaches will be required before this agent plays a role in liver transplant immunosuppression. See article by Klintmalm et al on page 1817.",

author = "Knechtle, {S. J.} and Adams, {A. B.}",

note = "Funding Information: The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. SJK is a stockholder of Bristol Myers Squibb. ABA receives grant money from Bristol Myers Squibb.",

year = "2014",

month = aug,

doi = "10.1111/ajt.12806",

language = "English (US)",

volume = "14",

pages = "1717--1718",

journal = "American Journal of Transplantation",

issn = "1600-6135",

publisher = "Wiley-Blackwell",

number = "8",

}

TY - JOUR

T1 - Belatacept

T2 - Is there BENEFIT for liver transplantation too?

AU - Knechtle, S. J.

AU - Adams, A. B.

N1 - Funding Information: The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. SJK is a stockholder of Bristol Myers Squibb. ABA receives grant money from Bristol Myers Squibb.

PY - 2014/8

Y1 - 2014/8

N2 - The results of the multicenter belatacept liver transplant trial disappoint with respect to safety and efficacy, and new approaches will be required before this agent plays a role in liver transplant immunosuppression. See article by Klintmalm et al on page 1817.

AB - The results of the multicenter belatacept liver transplant trial disappoint with respect to safety and efficacy, and new approaches will be required before this agent plays a role in liver transplant immunosuppression. See article by Klintmalm et al on page 1817.

UR - http://www.scopus.com/inward/record.url?scp=84904548450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904548450&partnerID=8YFLogxK

U2 - 10.1111/ajt.12806

DO - 10.1111/ajt.12806

M3 - Editorial

C2 - 25041120

AN - SCOPUS:84904548450

SN - 1600-6135

VL - 14

SP - 1717

EP - 1718

JO - American Journal of Transplantation

JF - American Journal of Transplantation

IS - 8

ER -

Belatacept: Is there BENEFIT for liver transplantation too?

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this